The potential of Anavex 2-73 as a therapy for a host of diverse diseases and conditions is yet little understood or perceived. Nonetheless, a wide diversity of diseases have been shown, at least in animal models, to be effective.
Unfortunately, as I’ve perused the postings and literature on 2-73 I’ve failed to document all of these potential applications. Presently, the lay public (day trading types, etc.) focus rather solely on 2-73 as a treatment for Alzheimer’s disease, perhaps Parkinson’s, and now, Rett’s syndrome. But, there are many others. And many of these are not neurological dysfunctions. A recent posting notes potential therapy for retinal deterioration in a particular disease or treatment scenario.
Yes, I have a small position in AVXL, and follow daily share price fluctuations. But I peruse the information on Anavex primarily as a biologist, not an investor. From that perspective I am extremely encouraged by two emerging stories about 2-73.
Most importantly — drug testing and approvals never occur otherwise — 2-73 simply does not produce side effect or adverse outcomes in any of the animal and human tests that have been conducted (and released). The molecule appears to work in rather low dosages, and appears not to adversely affect non-target organelles, organs, or organ systems. Every indication is that the stuff is safe.
Moreover, there is now indication that the molecule is authentically effective; therapeutic, at least for Alzheimer’s. No, full-scale human trials must yet be conducted to ascertain 2-73's efficacy in clinical applications in real human populations with Alzheimer’s, etc. Those, I’m certain, will occur (no, don’t know when or where). But if 2-73 can merely slow the progression or reduce the symptomatic severity of Alzheimer’s for any period of time, it will be approved. Current Alzheimer’s treatments primarily use acetylcholinesterase inhibitors, which yield merely a mild suppression of cognitive deficits, for only a short period of time. Approved, competing Alzheimer’s drugs have a very low clinical barrier over which 2-73 must jump. I have every assurance expanded human trials will reveal logarithmic suppression of AD symptoms, even reversal and/or prophylaxis (prevention).
Now, in full revelation, I have a mild form of hereditary spastic paraplegia, where certain motor neurons in my spinal cord are hyperactive, causing the adductors of my legs to be in constant tension. This apparently is a dysfunction of the mitochondria and endoplasmic reticula of my spinal motor neurons. I have good reason to believe that 2-73 will suppress or reverse the hyperexcitability of my affected motor neurons, restoring proper, normalized neuron physiology.
Again, 2-73 has never shown adverse results or side effects of any consequence, and its efficacy against an expanding list of human diseases continues to grow. The molecule is unique in each of these respects. It has the potential of revolutionizing medicine to the degree, or greater than, the appearance of antibiotics in the 40s and 50s.
I’m having fun watching all of this. (And thank the many who post clinical perspectives for our consideration.)
